Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.20    -1.80 (-2.65%)
Bid:
65.90
Ask:
66.70
Spread: 0.80 (1.214%)
Market Cap: £584.83m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Further re Scrip Dividend

29 Jun 2022 09:16

RNS Number : 6180Q
IP Group PLC
29 June 2022
 

FOR RELEASE ON

29 June 2022

 

IP Group plc - Further re Scrip Dividend

 

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, announces that further to the announcement made on 06 June 2022 in relation to the Scrip Dividend, the Group has received valid elections from certain shareholders. IP Group intends to sell Ordinary Shares which are currently held in treasury to satisfy such elections and will transfer these shares pursuant to the Scrip Dividend Terms and Conditions ("the Scrip Dividend Shares"). 

 

330,851 Scrip Dividend Shares will be transferred to relevant shareholders on 30 June 2022. Following such transfer, and in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Group will have 1,063,033,287 Ordinary Shares in issue and 28,607,622 shares in Treasury.

 

The total number of Ordinary Shares with voting rights following the satisfaction of the transfer will be 1,034,425,665 Ordinary Shares. This figure may be used by shareholders in the Group as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Group under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

David Baynes, Chief Financial and Operating OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7967 312125

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech (through Kiko Ventures). The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURMZGZVRLMGZZG
Date   Source Headline
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc
5th Aug 20207:00 amRNSHalf-yearly results
3rd Aug 20207:00 amRNSNanopore partners with govt on covid-19 test
30th Jul 202012:08 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
29th Jul 20209:45 amRNSHolding(s) in Company
28th Jul 20202:44 pmRNSNotice of Results
14th Jul 20201:29 pmRNSIP Group sells 9.16m shares in Ceres Power
14th Jul 20207:00 amRNSResult of secondary placing in Ceres Power
13th Jul 20205:11 pmRNSProposed secondary placing in Ceres Power Holdings
6th Jul 202012:02 pmRNSPrice Monitoring Extension
6th Jul 20207:00 amRNSAppoints Prof. Clark Chair of ESG Ethics Committee
3rd Jul 202012:07 pmRNSSecond Price Monitoring Extn
3rd Jul 202012:02 pmRNSPrice Monitoring Extension
24th Jun 20202:39 pmRNSHolding(s) in Company
24th Jun 20208:10 amRNSHolding(s) in Company
23rd Jun 202011:37 amRNSLTIP & DBSP awards; Director/PDMR shareholding
18th Jun 20202:05 pmRNSResult of AGM
18th Jun 20207:00 amRNSAGM Statement
9th Jun 20205:47 pmRNSAGM update
5th Jun 20206:28 pmRNSHolding(s) in Company
26th May 202010:05 amRNSInivata receives $25m investment from NeoGenomics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.